» Articles » PMID: 25930984

Assessing Antibody Strength: Comparison of MFI, C1q, and Titer Information

Overview
Journal Am J Transplant
Publisher Elsevier
Specialty General Surgery
Date 2015 May 2
PMID 25930984
Citations 73
Authors
Affiliations
Soon will be listed here.
Abstract

The presence of donor-specific HLA antibodies before or after transplantation may have different implications based on the antibody strength. Yet, current approaches do not provide information regarding the true antibody strength as defined by antigen-antibody dissociation rate. To assess currently available methods, we compared between neat mean fluorescence intensity (MFI) values, C1q MFI values, ethylenediaminetetraacetic acid (EDTA)-treated samples, as well as titration studies and peak MFI values of over 7000 Luminex-based single-antigen HLA antibody data points. Our results indicate that neat MFI values do not always accurately depict antibody strength. We further showed that EDTA treatment (6%) does not always remove all inhibitory factors compared with C1q or titration studies. In this study of patients presenting with multiple antibody specificities, a prozone effect was observed in 71% of the cohort (usually not affecting all antibody specificities within a single serum sample, though). Similar to titration studies, the C1q assay was able to address the issue of potential inhibition; however, its limitation is its low sensitivity and inability to detect the presence of weak antibodies. Titration studies are the only method among the approaches used in this study to provide information suggesting antigen-antibody dissociation rates and are, therefore, likely to provide better indication of true antibody strength.

Citing Articles

Understanding HLA-DQ in renal transplantation: a mini-review.

Das R, Greenspan N Front Immunol. 2025; 16:1525306.

PMID: 39975547 PMC: 11835797. DOI: 10.3389/fimmu.2025.1525306.


Follow-up biopsies with microvascular inflammation and persistent donor specific antibodies identify ongoing rejection in pediatric kidney transplant recipients.

Crane C, Mehrabli J, Ellington N, Shayan K, Morris G, Ingulli E Pediatr Nephrol. 2025; .

PMID: 39873804 DOI: 10.1007/s00467-025-06671-y.


Current and emerging tools for simultaneous assessment of infection and rejection risk in transplantation.

Tharmaraj D, Mulley W, Dendle C Front Immunol. 2024; 15:1490472.

PMID: 39660122 PMC: 11628869. DOI: 10.3389/fimmu.2024.1490472.


Anti-HLA Class II Antibodies Are the Most Resistant to Desensitization in Crossmatch-positive Living-donor Kidney Transplantations: A Patient Series.

de Weerd A, Roelen D, Betjes M, Clahsen-van Groningen M, Haasnoot G, Kho M Transplant Direct. 2024; 10(9):e1695.

PMID: 39220218 PMC: 11365629. DOI: 10.1097/TXD.0000000000001695.


Antibody-Mediated Rejection in Lung Transplantation: Diagnosis and Therapeutic Armamentarium in a 21st Century Perspective.

Messika J, Belousova N, Parquin F, Roux A Transpl Int. 2024; 37:12973.

PMID: 39170865 PMC: 11336419. DOI: 10.3389/ti.2024.12973.